Drug Type Antibody drug conjugate (ADC) |
Synonyms ACR246, ADC2154 |
Target |
Action inhibitors |
Mechanism 5T4 inhibitors(Trophoblast glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Oct 2024 | |
| Breast Cancer | Phase 2 | China | 21 Oct 2024 | |
| Colorectal Cancer | Phase 2 | China | 21 Oct 2024 | |
| Esophageal Carcinoma | Phase 2 | China | 21 Oct 2024 | |
| Kidney Neoplasms | Phase 2 | China | 21 Oct 2024 | |
| Non-Small Cell Lung Cancer | Phase 2 | China | 21 Oct 2024 | |
| Ovarian Cancer | Phase 2 | China | 21 Oct 2024 | |
| Pancreatic Cancer | Phase 2 | China | 21 Oct 2024 | |
| Prostatic Cancer | Phase 2 | China | 21 Oct 2024 | |
| Uterine Cervical Cancer | Phase 2 | China | 21 Oct 2024 |
Phase 1/2 | NKG2DL Positive Solid Tumors 5T4 positive | - | ypwrqvaqdg(tbrzmpjnkk) = dxhgisrtwj kotufoglkr (dswfjneudl ) | - | 30 May 2025 |






